Australia markets closed

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
44.68-0.86 (-1.89%)
At close: 04:03PM EST
46.76 +2.08 (+4.66%)
After hours: 06:28PM EST

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees19,000

Key executives

NameTitlePayExercisedYear born
Mr. John R. ChiminskiExec. Chair of the Board3.11M6.94M1964
Mr. Alessandro MaselliCEO & Director1.53MN/A1972
Mr. Thomas P. CastellanoSr. VP & CFO1.07MN/A1980
Mr. Steven L. Fasman Esq.Exec. VP, Corp. Sec. & Chief Admin. Officer1.3M1.34M1963
Dr. Aristippos Gennadios Ph.D.Group Pres of Pharma & Consumer Health Segment1.13MN/A1966
Mr. Ricky HopsonPres & Division Head for Clinical Devel. and SupplyN/AN/A1976
Ms. Karen Murphy SantiagoVP & Chief Accounting OfficeN/AN/A1971
Mr. Julien MeissonnierVP & Chief Scientific OfficerN/AN/AN/A
Mr. Charles LickfoldSr. VP & Chief Information OfficerN/AN/A1974
Mr. Paul SurdezVP of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Corporate governance

Catalent, Inc.’s ISS governance QualityScore as of 1 December 2022 is 7. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.